Test Price
2,800 AED✅ Home Collection Available
ALG13 Gene Glycosylation Disorder Type 1S Genetic Test in UAE | 2800 AED | DHA Approved
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance for result interpretation with a DHA-licensed genetic counsellor.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
The ALG13 Gene Glycosylation Disorder Type 1S Genetic Test is a definitive molecular diagnostic tool that analyses the entire coding region of the ALG13 gene using Next Generation Sequencing (NGS). It identifies pathogenic variants responsible for Congenital Disorder of Glycosylation Type 1S (CDG‑1S), a rare inherited metabolic condition that affects multiple organ systems. This test is utilised by physicians to detect causative mutations, enabling early intervention and precise therapeutic planning.
| Feature | Our Test (NGS) – Current Standard | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Diagnostic Precision | >99.9% sensitivity for point mutations & small indels | ~95% sensitivity; limited to known hotspot regions |
| Methodology | Next Generation Sequencing (Illumina platform, LC‑MS/MS validated) | Sanger dideoxy sequencing of individual exons |
| Turnaround Time | 3 to 4 Weeks (including confirmatory analysis) | 6 to 8 Weeks |
| Sample Options | Whole Blood, Extracted DNA, or One‑Drop Blood on FTA Card | Requires high‑quality extracted DNA |
| UAE Regulatory Compliance | Fully DHA audited, ISO 9001:2015, PDPL compliant | Variable; often sent abroad without local governance |
| Price (AED) | 2800 | 3600 – 4500 |
Physician Insight & Safety Protocols
“This NGS test provides a conclusive genetic diagnosis for children and adults with suspected CDG‑1S. However, no laboratory test stands alone; clinical correlation with physical findings, metabolite panels, and family history is essential. I strongly recommend comprehensive pre‑test genetic counselling to fully understand the implications of test results.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory
Do not discontinue any prescribed medication or start new supplements without explicit instruction from your treating physician. Certain anticonvulsants and dietary modifications must be supervised before and after testing.
Exclusion Criteria & Emergency Red Flags
Conditions Requiring Immediate Medical Attention
- Unstable acute metabolic crisis (e.g., severe hypoglycemia, hyperammonemia) – stabilise before sample collection.
- Known bleeding diathesis not managed by haematologist; use FTA card collection in such cases after consultation.
- Recent blood transfusion (<2 weeks) may interfere with germline DNA analysis – inform the lab.
- ER Red Flags: New‑onset seizures, loss of consciousness, or rapid neurological deterioration following sample collection – seek immediate emergency care.
- In paediatric patients, any sign of acute liver dysfunction or coagulopathy requires urgent medical evaluation.
Patient FAQ & Clinical Guidance
1. What is the ALG13 gene glycosylation disorder type 1S DNA test?
This advanced genetic test sequences the entire ALG13 gene using Next Generation Sequencing to identify disease‑causing mutations responsible for Congenital Disorder of Glycosylation Type 1S, providing a clear molecular diagnosis for affected families.
2. How accurate is the genetic test for glycosylation disorder type 1S?
Our ISO‑accredited NGS platform delivers >99.9% diagnostic sensitivity for single‑nucleotide variants and small insertions/deletions, making it the gold‑standard first‑tier genetic test for CDG‑1S when interpreted by expert clinical geneticists.
3. How should I prepare for the ALG13 glycosylation disorder DNA test?
You must attend a mandatory genetic counselling session to review your family history and draw a pedigree chart before sample collection; no fasting is required, and blood can be drawn via our VIP mobile phlebotomy home collection service.
UAE Regulatory & Data Privacy Adherence
Data Protection: This service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Clinical Safety: All procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability to ensure patient consent and clinical governance.
Laboratory Accreditation: Operates under DHA Facility License #1143, ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | ALG13 Gene Glycosylation Disorder Type 1S Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks (including confirmatory analysis) |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or One‑Drop Blood on FTA Card |
| Methodology Used | Next Generation Sequencing (Illumina platform, LC‑MS/MS validated) |
| ICD-10-CM Code | E77.8 |
| LOINC Code | 92651-7 |
| DHA Facility License & Laboratory Address | Licence #1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians